The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Progression-free survival after next line of treatment (PFS2) and subsequent therapies (subs tx) in the ASCENT-03 study of participants (pts) with previously untreated metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) vs chemotherapy (chemo).
 
Sara Hurvitz
Stock and Other Ownership Interests - ROM Tech (I)
Research Funding - Ambryx (Inst); Amgen (Inst); Arvinas (Inst); AstraZeneca/Daiichi Sankyo (Inst); Bayer (Inst); Biomarin (Inst); Cascadian Therapeutics (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dantari (Inst); Dignitana (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Greenwich LifeSciences (Inst); Immunomedics (Inst); Lilly (Inst); Loxo/Lilly (Inst); Macrogenics (Inst); Merrimack (Inst); Novartis (Inst); Orinove (Inst); Orum (Inst); Pfizer (Inst); Phoenix Molecular Designs (Inst); Pieris Pharmaceuticals (Inst); Puma Biotechnology (Inst); Radius Health (Inst); Samumed (Inst); sanofi (Inst); Seagen (Inst); Stemline/Menarini (Inst); Zymeworks (Inst)
Other Relationship - BeiGene (Inst); BMS (Inst); Boehringer Ingelheim; Briacell (Inst); BridgeBio Pharma (Inst); Celcuity; Embiosys; Gilead Sciences (Inst); InClin/Atossa; Jazz Pharmaceuticals (Inst); Luminate (Inst); Medsir; Mersana (Inst); Novartis; Pfizer; Roche; Roche (Inst)
 
Javier Cortes
Stock and Other Ownership Interests - Leuko (I); MAJ3 Capital
Honoraria - AstraZeneca; Celgene; Daiichi Sankyo; Eisai; Gilead Sciences; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Samsung; Steamline Therapeutics; Zuellig Pharma
Consulting or Advisory Role - Abbvie; AstraZeneca; Athenex; Bioasis; Biocon; Bioinvent; BioNTech SE; Bliss Biopharmaceutical; Boehringer Ingelheim; Bridgebio; Celgene; Cellestia Biotech; Circle Pharma; Clovis Oncology; Daiichi Sankyo; Delcath Systems; Ellipses Pharma; ERYTECH Pharma; Expres2ion Biotechnologies; GEMoaB; Gilead Sciences; GlaxoSmithKline; Hexagon Bio; HiberCell; Jazz Pharmaceuticals; Leuko; Lilly; Menarini; Merck Sharp & Dohme; Polyphor; Relay Therapeutics; Reveal Genomics; Roche; Seagen; SERVIER; Zymeworks
Research Funding - ARIAD (Inst); Astrazeneca (Inst); Baxalta (Inst); Bayer (Inst); Eisai (Inst); Guardant Health (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Piqur (Inst); Puma Biotechnology (Inst); Queen Mary university of London (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy.Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/ 0338368 A1; Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A.
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Merck Sharp&Dhome; Novartis; Pfizer; Roche; Steamline Therapeutics
 
Sara Tolaney
Consulting or Advisory Role - AADi; Aktis Oncology; Ambrx; Arvinas; AstraZeneca; Avenzo Therapeutics; Bayer; BeiGene; Bicycle Therapeutics; BioNTech; Boehringer Ingelheim; Boundless Bio; Bristol-Myers Squibb; Celcuity; Circle Pharma; Corcept Therapeutics; Cullinan Oncology; Daiichi Sankyo; Denali Therapeutics; eFFECTOR Therapeutics; Eisai; Ellipses Pharma; Genentech; Immunomedics/Gilead; Jazz Pharmaceuticals; Johnson & Johnson; Launch Therapeutics; Lilly; Menarini Group; Merck; Mersana; Novartis; Olema Pharmaceuticals; Pfizer; Reveal Genomics; Samsung Bioepis; Seagen; Summit Therapeutics; Systimmune; Tempus; Zuellig Pharma
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo; Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Menarini/Stemlin (Inst); Merck (Inst); NanoString Technologies (Inst); Novartis (Inst); Olema Pharmaceuticals (Inst); OncoPep (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Arvinas; AstraZeneca; Gilead Sciences; Jazz Pharmaceuticals; Lilly; Pfizer; Roche
(OPTIONAL) Uncompensated Relationships - AstraZeneca; Gilead Sciences
 
Kevin Punie
Consulting or Advisory Role - AstraZeneca; Eisai; Exact Sciences; Focus Patient; Gilead Sciences; Lilly; Medscape; Menarini; MSD; Mundipharma; Need; Nordic Group; Novartis; Pfizer; Roche; Sanofi; Sanofi; Seagen
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Gilead Sciences; Lilly; MSD; Pfizer
 
Andreas Schneeweiss
Honoraria - Amgen; AstraZeneca; Aurikamed; ClinSol; coma UroGyn; Connectmedica; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; I-MED; if-kongress; iOMEDICO; Lilly; MCI Deutschland; MSD; Novartis; Onkowissen; Pfizer; Promedicis; Roche; Seagen; Streamedup!
Research Funding - Roche Pharma AG (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Gilead Sciences; Pfizer; Roche
 
Joohyuk Sohn
Stock and Other Ownership Interests - Daiichi Sankyo (I)
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol Myerss guibb (Inst); Celcuity (Inst); CENTESSA PHARMACEUTICAL (Inst); Daiichi Sankyo (Inst); Dragonfly Therapeutics (Inst); Eikon (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hanmi Pharm (Inst); HLB Life Science (Inst); ILDONG PHARMACEUTICAL (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Olema Oncology (Inst); Pfizer (Inst); Qurient (Inst); Roche (Inst); Samyang Holdings (Inst); Sanofi (Inst); Seagan (Inst); Sermonix Pharmaceuticals (Inst)
 
Eriko Tokunaga
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Geliad; Lilly Japan
 
Adam Brufsky
Consulting or Advisory Role - Agendia; Ataraxis; Celcuity; Daiichi Sankyo/Lilly; Genentech/Roche; General Electric; Gilead Sciences; Lilly; Merck; Novartis; Pfizer; Puma Biotechnology
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst)
Expert Testimony - Pfizer; Sanofi
 
Yeon Hee Park
Honoraria - AimedBio; AstraZeneca; BeOne; BMS; Daiichi-Sankyo; Eisai; Gilead Sciences; Helsinn Healthcare; Lilly; MSD; Novartis; Pfizer; Roche; Voronoi Health Analytics
Consulting or Advisory Role - AimedBio; AstraZeneca; BMS; Boryung; Daiichi-Sankyo; Eisai; Gilead Sciences; Helsinn Therapeutics; Jazz Pharmaceuticals; Lilly; Menarini; MSD; Novartis; Pfizer; Roche; Voronoi Health Analytics
Research Funding - AstraZeneca; Boryung; Daewoong Pharmaceutical; Gencurix; Gencurix (Inst); Gilead Sciences; Inocras; Inocras (Inst); Kirin Pharmaceuticals; NGeneBio (Inst); Pfizer; Roche (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Gilad; Helsinn Therapeutics; Jazz Pharmaceuticals; Novartis; Pfizer; Roche
 
Binghe Xu
Consulting or Advisory Role - AstraZeneca; Novartis
 
Roberto Hegg
No Relationships to Disclose
 
Mafalda Oliveira
Honoraria - AstraZeneca; Curio Science; Gilead Sciences; i-One; Lilly; MSD
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; ProteinQure; Roche
Research Funding - AstraZeneca (Inst); Gilead Sciences (Inst); Immutep (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - AstraZeneca Spain; Gilead Sciences; Pfizer; Roche
(OPTIONAL) Uncompensated Relationships - President elected, SOLTI Cancer Research Group
 
Alessandra Fabi
Employment - ASTRA ZENECA ITALIA; Daichii Sankyo; dompè biotech; Lilly; Menarini Group; MSK Pharma; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Menarini Group; MSD Oncology; MSD Oncology; Roche
Research Funding - ASTRA ZENA
 
Xinrui Zhang
Employment - Gilead Sciences; Novartis
Stock and Other Ownership Interests - Gilead Sciences; Novartis
Travel, Accommodations, Expenses - Gilead Sciences
 
Hao Wang
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Anh Nguyen
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
Travel, Accommodations, Expenses - Gilead Sciences
 
Natalya Vaksman
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Carlos Barrios
Stock and Other Ownership Interests - CPO; MedSIR; Thummi
Honoraria - Adium Pharma; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; MSD Oncology; Novartis; Pfizer; Roche/Genentech
Research Funding - Amgen (Inst); AstraZeneca (Inst); Aveo (Inst); BioNTech SE (Inst); BMS Brazil (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Dizal Pharma (Inst); Exelixis (Inst); Exelixis (Inst); FORTREA (Inst); FORTREA (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); ICON Clinical Research (Inst); IQvia (Inst); Janssen (Inst); LabCorp (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Novocure (Inst); Nuvisan (Inst); OBI Pharma (Inst); Parexel (Inst); Pfizer (Inst); PharmaMar (Inst); PPD Global (Inst); PSI (Inst); Regeneron (Inst); Roche/Genentech (Inst); Samsung (Inst); Sandoz (Inst); Sanofi (Inst); Servier (Inst); Sremline (Inst); Syneos Health (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TRIO US (Inst); Worldwide Clinical Trials (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BMS Brazil; Lilly; MSD Oncology; Novartis; Pfizer; Roche/Genentech